|1.||McGrath, J J: 2 articles (01/2001 - 01/2000)|
|2.||Soares, K V: 2 articles (01/2001 - 01/2000)|
|3.||Deeks, J J: 2 articles (01/2001 - 01/2000)|
|4.||Rejdak, Konrad: 1 article (06/2014)|
|5.||Turski, Waldemar A: 1 article (06/2014)|
|6.||Czuczwar, Mirosław: 1 article (06/2014)|
|7.||Kiś, Jacek: 1 article (06/2014)|
|8.||Nieoczym, Dorota: 1 article (06/2014)|
|9.||Wlaź, Piotr: 1 article (06/2014)|
|10.||Mohammad, Husam Aldeen: 1 article (01/2011)|
06/01/1987 - "A controlled study of progabide in partial seizures: methodology and results."
12/01/1983 - "Twenty-four patients entered the study: three dropped out for reasons unrelated to progabide effects; one dropped out during the placebo period because of increased seizure frequency. "
01/01/1995 - "Gabrene (25, 50, 100 and 250 mg/kg i.p.) inhibited PTZ-kindled seizures. "
01/01/1988 - "Preliminary observations on the activity of progabide, administered as monotherapy in complex partial seizures."
02/01/1986 - "A mean daily dose of 32 mg/kg (range, 16 to 63) of progabide did not significantly change the seizure frequency. "
01/01/1984 - "Progabide has been shown to be effective in various forms of epilepsy in double-blind and long-term clinical trials. "
10/01/1984 - "Progabide treatment in severe epilepsy: a double-blind cross-over trial versus placebo."
12/01/1983 - "Double-blind crossover trial of progabide versus placebo in severe epilepsies."
01/01/1983 - "progabide, accounts for their efficacy in epilepsy."
06/29/1984 - "Progabide as an add-on drug for epilepsy refractory to high dose antiepileptic drug therapy."
01/01/1985 - "These results suggest that progabide can be useful in the treatment of neuroleptic-induced dyskinesia."
06/01/1987 - "In the second trial, 20 patients with neuroleptic-induced dyskinesia (TD) entered an open dose ranging trial with progabide. "
06/01/1987 - "No change was observed during this trial in the severity of dyskinesia on progabide treatment but the drug significantly extended the "on" period as compared with placebo. "
01/01/1985 - "Twenty-nine patients suffering from neuroleptic-induced dyskinesia have been treated in three studies (two open, one double-blind cross over) with progabide at doses from 900 to 2400 mg/day; clinical evaluation and EMG testing are in favor of a therapeutic effect of progabide on dyskinesia. "
01/01/1985 - "The possible mechanism of action of progabide in dyskinesia is discussed in the light of its pharmacological properties. "
|4.||Movement Disorders (Movement Disorder)
02/25/1992 - "These data would suggest that progabide and perhaps other GABAmimetic compounds can prevent the development of tardive dyskinesia in man."
09/01/1985 - "Progabide in the treatment of hyperkinetic extrapyramidal movement disorders."
01/01/1985 - "At variance with studies in tardive dyskinesia progabide was not effective in this kind of dyskinesia but an increase in the "on" time has been observed in both studies. "
01/01/1994 - "Previously, we have reported a reduction in these haloperidol-induced oral dyskinesias with the coadministration of a direct acting GABA agonist progabide. "
02/25/1992 - "Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats."
|5.||Partial Epilepsies (Epilepsy, Partial)
02/01/1986 - "Progabide for refractory partial epilepsy: a controlled add-on trial."
04/01/1983 - "Progabide: a controlled trial in partial epilepsy."
06/29/1984 - "Progabide appears to be as effective as primary antiepileptic drug for adjunctive therapy in partial epilepsy refractory to previous high-dose therapy. "
02/01/1986 - "Progabide, an experimental GABA-ergic antiepileptic drug, was given in a placebo-controlled double-blind cross-over trial to 19 adult patients with chronic partial epilepsy refractory to previous high-dose antiepileptic drug therapy. "
|1.||GABA Agonists (GABA Receptor Agonists)
|5.||Ethanol (Ethyl Alcohol)
|6.||gamma-Aminobutyric Acid (GABA)
|9.||GABA Receptors (GABA Receptor)
|10.||Anticonvulsants (Antiepileptic Drugs)
|1.||Drug Therapy (Chemotherapy)